Chapter 2 CCR5 Pharmacology Methodologies and Associated Applications

Methods in Enzymology

Volumn 460, Issue A, 2009, Pages 17-55

  Mansfield, Roy ^a   Able, Sarah ^a   Griffin, Paul ^a   Irvine, Becky ^a   James, Ian ^a   Macartney, Malcolm ^a   Miller, Ken ^b   Mills, James ^a   Napier, Carolyn ^a   Navratilova, Iva ^a   Perros, Manos ^a   Rickett, Graham ^a   Root, Harriet ^a   van der Ryst, Elna ^a   Westby, Mike ^a   Dorr, Patrick ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; APLAVIROC; CALCIUM; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLIC AMP; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GUANOSINE TRIPHOSPHATE; MARAVIROC; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D4; PF 232798; PF 501606; UK 107543; UK 396794; UK 433370; UK 438235; UK 484900; UNCLASSIFIED DRUG; VICRIVIROC; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BINDING ASSAY; CALCIUM ANTAGONISM; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL CULTURE; CELL FUSION; CELL SURFACE; DNA RESPONSIVE ELEMENT; DRUG BINDING; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFLAMMATION; INTERNALIZATION; ISOTOPE LABELING; LIGAND BINDING; MACROPHAGE; MEDICAL RESEARCH; METHODOLOGY; MONOCYTE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; REPORTER GENE; REVIEW; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; VIRUS REPLICATION; VIRUS RESISTANCE; ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG DEVELOPMENT; GENETICS; METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTI-HIV AGENTS; CYCLOHEXANES; DRUG DISCOVERY; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; TRIAZOLES;

EID: 65549130587     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(09)05202-1     Document Type: Review

References (46)

1. Blanpain C., Doranz B.J., Bondue A., Govaerts C., De Leener A., Vassart G., Doms R.W., Proudfoot A., and Parmentier M. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J. Biol. Chem. 278 (2003) 5179-5187 Epub 2002 Dec 3
2. Bradley J., Gill J., Bertelli F., Letafat S., Corbau R., Hayter P., Harrison P., Tee A., Keighley W., Perros M., Ciaramella G., Sewing A., et al. Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry. J. Biomol. Screen 9 (2004) 516-524
3. Combadiere C., Ahuja S.K., Tiffany H.L., and Murphy P.M. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J. Leukoc. Biol. 60 (1996) 147-152
4. Dobbs S., Perros M., and Rickett G.A. An assay method for determining whether an agent is capable of mudlating the interaction of CCR5 with gp120 (2001)
5. Dorr P., and Perros M. CCR5 inhibitors in HIV therapy. Expert Opinion for Drug Discovery 3 (2008) 1-16
6. Dorr P., Corbau R., Pickford C., Rickett G., Macartney M., Griffin P., Dobbs S., Irvine R., Westby M., and Perros M. Evaluation of the mechanism underlying the anti-HI activity of a series of experimental CCR5 antagonists. 43rd Annual Interscience Conference Antimicrobial Agents and Chemotherapy. Sept 14-17 2003 (2003), Poster, Chicago F1466
7. Dorr P., and Perros M. CCR5 inhibitors in HIV therapy. Expert Opinion for Drug Discovery 3 (2008) 1345-1361
8. Dorr P., Rickett G., and Perros M. A method for identifying CCR5 receptor antagonists by measuring residency time. Patent Ref. US20040023845 A1 (2003)
9. Dorr P., Todd K., Irvine B., Robas N., Thomas A., Fidock M., Sultan H., Mills J., Perrucio F., Burt C., Rickett G., Perkins H., et al. Site-Directed Mutagenesis Studies of CCR5 Reveal Differences in the Interactions between the Receptor and Various CCR5 Antagonists. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (2005)
10. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., Mori J., Rickett G., Smith-Burchnell C., Napier C., Webster R., Armour D., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49 (2005) 4721-4732
11. Dorr P., Westby M., McFadyen L., Mori J., Davis J., Perruccio F., Jones R., Stupple P., Middleton D., and Perros M. PF-232798, a Second Generation Oral CCR5 Antagonist. 15th Conference on Retroviruses and Opportunistic Infections, Boston. (Boston). February, 2008 (2008) 3-6 Abstract 737
12. Dorr P. Maraviroc outlook in HIV and non-HIV diseases. HIV-Infection and Organ Transplantation Symposium (2008), University Medical Center Hamburg-Eppendorf Hamburg, Germany
13. Haworth B., Lin H., Fidock M., Dorr P., and Strange P.G. Allosteric effects of antagonists on signalling by the chemokine receptor CCR5. Biochem. Pharmacol. 74 (2007) 891-897 Epub 2007 Jun 26
14. Hooper M., Hardy K., Handyside A., Hunter S., and Monk M. HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature 326 (1987) 292-295
15. Jansson C.C., Pohjanoksa K., Lang J., Wurster S., Savola J.M., and Scheinin M. Alpha2-adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner. Eur. J. Pharmacol. 374 (1999) 137-146
16. Kenakin T., Jenkinson S., and Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J. Pharmacol. Exp. Ther. 319 (2006) 710-723 Epub 2006 Jul 20
17. Kondru R., Zhang J., Ji C., Mirzadegan T., Rotstein D., Sankuratri S., and Dioszegi M. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73 (2008) 789-800 Epub 2007 Dec 20
18. Labrecque J., Anastassov V., Lau G., Darkes M., Mosi R., and Fricker S.P. The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5. Assay Drug Dev. Technol. 3 (2005) 637-648
19. Lakso M., Pichel J.G., Gorman J.R., Sauer B., Okamoto Y., Lee E., Alt F.W., and Westphal H. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc. Natl. Acad. Sci. USA 93 (1996) 5860-5865
20. Mirzabekov T., Bannert N., Farzan M., Hofmann W., Kolchinsky P., Wu L., Wyatt R., and Sodroski J. Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor. J. Biol. Chem. 274 (1999) 28745-28750
21. Mosier D.E., Picchio G.R., Gulizia R.J., Sabbe R., Poignard P., Picard L., Offord R.E., Thompson D.A., and Wilken J. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73 (1999) 3544-3550
22. Mosley M., Pullen S., Botham A., Gray A., Napier C., Mansfield R., and Holbrook M. The molecular cloning and functional expression of the dog CCR5. Vet Immunol. Immunopathol. 113 (2006) 415-420 Epub 2006 Jun 27
23. Mueller A., Mahmoud N.G., Goedecke M.C., McKeating J.A., and Strange P.G. Pharmacological characterization of the chemokine receptor, CCR5. Br. J. Pharmacol. 135 (2002) 1033-1043
24. Mueller A., Mahmoud N.G., and Strange P.G. Diverse signalling by different chemokines through the chemokine receptor CCR5. Biochem. Pharmacol. 72 (2006) 739-748 Epub 2006 Jul 17
25. Mueller A., and Strange P.G. CCL3, acting via the chemokine receptor CCR5, leads to independent activation of Janus kinase 2 (JAK2) and Gi proteins. FEBS Lett. 570 (2004) 126-132
26. Mueller A., and Strange P.G. The chemokine receptor, CCR5. Int. J. Biochem. Cell. Biol. 36 (2004) 35-38
27. Napier C., Sale H., Mosley M., Rickett G., Dorr P., Mansfield R., and Holbrook M. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem. Pharmacol. 71 (2005) 163-172 Epub 2005 Nov. 18
28. Navratilova I., Dioszegi M., and Myszka D.G. Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology. Anal. Biochem. 355 (2006) 132-139 Epub 2006 May 15
29. Oprian D.D., Molday R.S., Kaufman R.J., and Khorana H.G. Expression of a synthetic bovine rhodopsin gene in monkey kidney cells. Proc. Natl. Acad. Sci. USA 84 (1987) 8874-8878
30. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., and Miyano M. Crystal structure of rhodopsin: A G. protein-coupled receptor. Science 289 (2000) 739-745
31. Peltonen J.M., Pihlavisto M., and Scheinin M. Subtype-Specific Stimulation of [S-35]Gtp-Gamma-S Binding by Recombinant Alpha(2)-Adrenoceptors. European Journal of Pharmacology 355 (1998) 275-279
32. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., Tian H., Smith D., Winslow G.A., Capon D.J., and Whitcomb J.M. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44 (2000) 920-928
33. Rickett G., Dobbs S., Griffin P., Dorr P., Hitchcock C., and Perros M. Development of a high throughput time resolved immunoassay to support discovery of HIV-1 entry inhibitors. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (2003) Abstract F-1461
34. Sauer B., and Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc. Natl. Acad. Sci. USA 85 (1988) 5166-5170
35. Strizki J.M., Tremblay C., Xu S., Wojcik L., Wagner N., Gonsiorek W., Hipkin R.W., Chou C.C., Pugliese-Sivo C., Xiao Y., Tagat J.R., Cox K., et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49 (2005) 4911-4919
36. Strizki J.M., Xu S., Wagner N.E., Wojcik L., Liu J., Hou Y., Endres M., Palani A., Shapiro S., Clader J.W., Greenlee W.J., Tagat J.R., et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98 22 (2001) 12718-12723
37. Tagat J.R., McCombie S.W., Nazareno D., Labroli M.A., Xiao Y., Steensma R.W., Strizki J.M., Baroudy B.M., Cox K., Lachowicz J., Varty G., and Watkins R. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperaz inyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J. Med. Chem. 47 (2004) 2405-2408
38. Tsamis F., Gavrilov S., Kajumo F., Seibert C., Kuhmann S., Ketas T., Trkola A., Palani A., Clader J.W., Tagat J.R., McCombie S., Baroudy B., et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77 (2003) 5201-5208
39. Tsamis F., Gavrilov S., Kajumo F., Seibert C., Kuhmann S., Ketas T., Trkola A., Palani A., Clader J.W., Tagat J.R., McCombie S., Baroudy B., et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77 (2003) 5201-5208
40. Turner J.E., Steinmetz O.M., Stahl R.A., and Panzer U. Targeting of Th1-associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for inflammatory diseases. Mini Rev. Med. Chem. 7 (2007) 1089-1096
41. Watson C., Jenkinson S., Kazmierski W., and Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67 (2005) 1268-1282
42. Watson C., Jenkinson S., Kazmierski W., and Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67 (2005) 1268-1282 Epub 2005 Jan. 11
43. Wells T.N., Power C.A., Shaw J.P., and Proudfoot A.E. Chemokine blockers--therapeutics in the making?. Trends Pharmacol. Sci. 27 (2006) 41-47 Epub 2005 Nov. 28
44. Westby M., Smith-Burchnell C., Hamilton D., Robas N., Irvine B., Fidock M., Mills J., Perruccio F., Mori J., Macartney M., Barber C., Dorr P., et al. UK-427,857-resistant Primary Isolates are Susceptible to Structurally-related CCR5 Antagonists. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA (2005)
45. Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., Dorr P., Ciaramella G., and Perros M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81 (2007) 2359-2371
46. Westby M., Smith-Burchnell C., Mori J., Lewis M., Whitcomb J., Petropoulos C., and Perros M. In vitro Escape of R5 Primary Isolates from the CCR5 Antagonist, UK-427,857, is Difficult to Achieve and Involves Continued Use of the CCR5 Receptor. XIII International HIV Drug Resistance Workshop, Tenerife (2004)